Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Research

microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer

Authors: Stephanie Geisler Crone, Anders Jacobsen, Birgitte Federspiel, Linda Bardram, Anders Krogh, Anders H Lund, Lennart Friis-Hansen

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Background

Gastric cancer is the second most common cause of cancer-related death in the world. Inflammatory signals originating from gastric cancer cells are important for recruiting inflammatory cells and regulation of metastasis of gastric cancer. Several microRNAs (miRNA) have been shown to be involved in development and progression of gastric cancer. miRNA-146a (miR-146a) is a modulator of inflammatory signals, but little is known about its importance in gastric cancer. We therefore wanted to identify targets of miR-146a in gastric cancer and examine its biological roles.

Results

The expression of miR-146a was evaluated by quantitative PCR (qPCR) and found up-regulated in the gastrin knockout mice, a mouse model of gastric cancer, and in 73% of investigated human gastric adenocarcinomas. Expression of miR-146a by gastric cancer cells was confirmed by in situ hybridization. Global analysis of changes in mRNA levels after miR-146a transfection identified two transcripts, caspase recruitment domain-containing protein 10 (CARD10) and COP9 signalosome complex subunit 8 (COPS8), as new miR-146a targets. qPCR, Western blotting and luciferase assays confirmed these transcripts as direct miR-146a targets. CARD10 and COPS8 were shown to be part of the G protein-coupled receptor (GPCR) pathway of nuclear factor-kappaB (NF-kappaB) activation. Lysophosphatidic acid (LPA) induces NF-kappaB activation via this pathway and over-expression of miR-146a inhibited LPA-induced NF-kappaB activation, reduced LPA-induced expression of tumor-promoting cytokines and growth factors and inhibited monocyte attraction.

Conclusions

miR-146a expression is up-regulated in a majority of gastric cancers where it targets CARD10 and COPS8, inhibiting GPCR-mediated activation of NF-kappaB, thus reducing expression of NF-kappaB-regulated tumor-promoting cytokines and growth factors. By targeting components of several NF-kappaB-activating pathways, miR-146a is a key component in the regulation of NF-kappaB activity.
Appendix
Available only for authorised users
Literature
1.
2.
Persson C, Canedo P, Machado JC, El-Omar EM, Forman D: Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol. 2011, 173: 259-270.PubMedCentralCrossRefPubMed
3.
Yamaoka Y: Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol. 2010, 7: 629-641.PubMedCentralPubMed
4.
Peleteiro B, Lopes C, Figueiredo C, Lunet N: Salt intake and gastric cancer risk according to Helicobacter pylori infection, smoking, tumour site and histological type. Br J Cancer. 2011, 104: 198-207.PubMedCentralCrossRefPubMed
5.
Hohenberger P, Gretschel S: Gastric cancer. Lancet. 2003, 362: 305-315.PubMed
6.
Cappetta A, Lonardi S, Pastorelli D, Bergamo F, Lombardi G, Zagonel V: Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Crit Rev Oncol Hematol. 2012, 81: 38-48.PubMed
7.
Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, Kuraoka K, Nakayama H, Yasui W: Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res. 2004, 64: 2397-2405.CrossRefPubMed
8.
Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ: Dysregulation of cellular signaling in gastric cancer. Cancer Lett. 2010, 295: 144-153.CrossRefPubMed
9.
10.
11.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006, 103: 2257-2261.PubMedCentralCrossRefPubMed
12.
Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11: 136-146.PubMedCentralCrossRefPubMed
13.
Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009, 24: 652-657.CrossRefPubMed
14.
15.
16.
Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006, 103: 12481-12486.PubMedCentralCrossRefPubMed
17.
Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, Lithgow GJ, Campisi J: MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany NY). 2009, 1: 402-411.
18.
Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X: MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol. 2009, 183: 2150-2158.CrossRefPubMed
19.
Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA: Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans. 2008, 36: 1211-1215.CrossRefPubMed
20.
21.
Tchernitsa O, Kasajima A, Schafer R, Kuban RJ, Ungethum U, Gyorffy B, Neumann U, Simon E, Weichert W, Ebert MP, Rocken C: Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol. 2010, 222: 310-319.CrossRefPubMed
22.
Kogo R, Mimori K, Tanaka F, Komune S, Mori M: Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res. 2011, 17: 4277-4284.CrossRefPubMed
23.
Hou Z, Xie L, Yu L, Qian X, Liu B: MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis. Med Oncol. 2012, 29: 886-892.CrossRefPubMed
24.
Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, Han S, Nie Y, Chen X, Zhao Q, Ding J, Wu K, Daiming F: miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 2011, 9: 824-833.CrossRefPubMed
25.
Friis-Hansen L, Rieneck K, Nilsson HO, Wadstrom T, Rehfeld JF: Gastric inflammation, metaplasia, and tumor development in gastrin-deficient mice. Gastroenterology. 2006, 131: 246-258.CrossRefPubMed
26.
Wen J, Parker BJ, Jacobsen A, Krogh A: MicroRNA transfection and AGO-bound CLIP-seq data sets reveal distinct determinants of miRNA action. RNA. 2011, 17: 820-834.PubMedCentralCrossRefPubMed
27.
Grabiner BC, Blonska M, Lin PC, You Y, Wang D, Sun J, Darnay BG, Dong C, Lin X: CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{ kappa} B activation. Genes Dev. 2007, 21: 984-996.PubMedCentralCrossRefPubMed
28.
Welteke V, Eitelhuber A, Duwel M, Schweitzer K, Naumann M, Krappmann D: COP9 signalosome controls the Carma1-Bcl10-Malt1 complex upon T-cell stimulation. EMBO Rep. 2009, 10: 642-648.PubMedCentralCrossRefPubMed
29.
30.
Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J: miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011, 208: 1189-1201.PubMedCentralCrossRefPubMed
31.
Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC: Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008, 27: 5643-5647.PubMedCentralCrossRefPubMed
32.
Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M, Katano M: Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res. 2001, 7: 4136-4142.PubMed
33.
Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y: Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009, 5: e1000676-PubMedCentralCrossRefPubMed
34.
35.
Su H, Huang W, Wang X: The COP9 signalosome negatively regulates proteasome proteolytic function and is essential to transcription. Int J Biochem Cell Biol. 2009, 41: 615-624.PubMedCentralCrossRefPubMed
36.
Lei D, Li F, Su H, Tian Z, Ye B, Wei N, Wang X: COP9 signalosome subunit 8 is required for postnatal hepatocyte survival and effective proliferation. Cell Death Differ. 2011, 18: 259-270.PubMedCentralCrossRefPubMed
37.
Murray D, Horgan G, Macmathuna P, Doran P: NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancer. Br J Cancer. 2008, 99: 1322-1329.PubMedCentralCrossRefPubMed
38.
Li N, Xu X, Xiao B, Zhu ED, Li BS, Liu Z, Tang B, Zou QM, Liang HP, Mao XH: H. pylori related proinflammatory cytokines contribute to the induction of miR-146a in human gastric epithelial cells. Mol Biol Rep. 2012, 39: 4655-4661.CrossRefPubMed
39.
Ben-Baruch A: Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006, 16: 38-52.CrossRefPubMed
40.
Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW: Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol. 2006, 80: 1183-1196.CrossRefPubMed
41.
Oz-Arslan D, Ruscher W, Myrtek D, Ziemer M, Jin Y, Damaj BB, Sorichter S, Idzko M, Norgauer J, Maghazachi AA: IL-6 and IL-8 release is mediated via multiple signaling pathways after stimulating dendritic cells with lysophospholipids. J Leukoc Biol. 2006, 80: 287-297.CrossRefPubMed
42.
Chen SU, Chou CH, Lee H, Ho CH, Lin CW, Yang YS: Lysophosphatidic acid up-regulates expression of interleukin-8 and −6 in granulosa-lutein cells through its receptors and nuclear factor-kappaB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2008, 93: 935-943.CrossRefPubMed
43.
44.
He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005, 102: 19075-19080.PubMedCentralCrossRefPubMed
45.
Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008, 3: e2557-PubMedCentralCrossRefPubMed
46.
Pacifico F, Crescenzi E, Mellone S, Iannetti A, Porrino N, Liguoro D, Moscato F, Grieco M, Formisano S, Leonardi A: Nuclear factor-{ kappa} B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a. J Clin Endocrinol Metab. 2010, 95: 1421-1430.CrossRefPubMed
47.
Schweitzer K, Naumann M: Control of NF-kappaB activation by the COP9 signalosome. Biochem Soc Trans. 2010, 38: 156-161.CrossRefPubMed
48.
49.
50.
51.
Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, von Stedingk K, Ghesquiere B, Schulte S, Dews M: The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell. 2010, 40: 762-773.PubMedCentralCrossRefPubMed
52.
Papagiannakopoulos T, Shapiro A, Kosik KS: MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008, 68: 8164-8172.CrossRefPubMed
53.
Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K: Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes?. Gastric Cancer. 2010, 13: 212-221.CrossRefPubMed
54.
Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M: IL-23 promotes tumour incidence and growth. Nature. 2006, 442: 461-465.CrossRefPubMed
55.
Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X, Fang G: The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun. 2008, 374: 533-537.CrossRefPubMed
56.
Cao R, Bjorndahl MA, Religa P, Clasper S, Garvin S, Galter D, Meister B, Ikomi F, Tritsaris K, Dissing S: PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 2004, 6: 333-345.CrossRefPubMed
57.
Ostman A, Augsten M: Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr Opin Genet Dev. 2009, 19: 67-73.CrossRefPubMed
58.
59.
Mancino A, Lawrence T: Nuclear factor-kappaB and tumor-associated macrophages. Clin Cancer Res. 2010, 16: 784-789.CrossRefPubMed
60.
Mantovani A, Schioppa T, Porta C, Allavena P, Sica A: Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006, 25: 315-322.CrossRefPubMed
61.
Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, Illgen-Wilcke B: Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim. 2002, 36: 20-42.CrossRefPubMed
62.
Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008, 283: 1026-1033.CrossRefPubMed
63.
Jacobsen A, Wen J, Marks DS, Krogh A: Signatures of RNA binding proteins globally coupled to effective microRNA target sites. Genome Res. 2010, 20: 1010-1019.PubMedCentralCrossRefPubMed
64.
Jorgensen S, Baker A, Moller S, Nielsen BS: Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods. 2010, 52: 375-381.CrossRefPubMed
65.
66.
Cowland JB, Sorensen OE, Sehested M, Borregaard N: Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol. 2003, 171: 6630-6639.CrossRefPubMed
67.
Boyum A: Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl. 1968, 97: 7.PubMed
Metadata
Title
microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer
Authors
Stephanie Geisler Crone
Anders Jacobsen
Birgitte Federspiel
Linda Bardram
Anders Krogh
Anders H Lund
Lennart Friis-Hansen
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-71

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue

Research

Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion

Research

Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin

Research

miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer

Research

Nicotine, IFN-γ and retinoic acid mediated induction of MUC4 in pancreatic cancer requires E2F1 and STAT-1 transcription factors and utilize different signaling cascades

Research

Inhibition of Phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model

Research

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits